Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Medico Remedies receives order worth US$ 1,781,000
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Subscribe To Our Newsletter & Stay Updated
